oncology
Cancer care

Treatment-free remission achieved in CML patients with second-line nilotinib

Long term treatment free remission can be achieved in most chronic myeloid leukaemia patients who show a deep molecular response with second-line nilotinib therapy, researchers from South Australia have shown in a multinational trial. The findings come from a trial led by researchers from South Australian Health and Medical Research Institute, who studied 163 patients ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic